Dr. Brad Worthington and his friend, Thurman Ballard, needed to commit to one of three possible paths for commercializing BKK, their new combination drug. BKK was a unique, patented formulation of nonopioid anesthesia drugs with an excellent record in practice. Because BKK was based on the synergistic use of three FDA-approved drugs, it could be used without additional approvals. Worthington and Ballard could pursue a New Drug Application, partner with a compounding pharmacy to sell BKK as a premixed product, or opt to sell a convenience kit containing BKK's premeasured components, attractively boxed but not premixed. Each path held risks and promise. Which should they choose?